← Leaderboards
Ravi Bhatia
University Of Alabama At Birmingham
$16,631,024
Attributed
$16,631,024
Total exposure
23
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,103,668 · 24
By mechanism
R01$13,787,104 · 5
U54$2,472,644 · 1
P50$1,927,786 · 2
T32$467,045 · 1
M01$303,989 · 13
R29$103,600 · 1
Top collaborators
- Upender Manne2 shared
- Isabel C Scarinci2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Elizabeth Ann Eklund$14,527,585
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaHematopoietic Stem CellsResponseRegulationPlayResistanceSignal TransductionGrowthTyrosine Kinase InhibitorCellsDisease RemissionRelapseChronic Myeloid LeukemiaHematopoieticBone MarrowGrantBaseMouse ModelBcr-Abl Fusion ProteinsProtein Tyrosine KinaseCell MaintenanceGene ExpressionGenesMaintenance
Grant awards (70)
Leukemia stem cell regulation and resistance$425,243
R01 · FY2025 · CA · contact PI
Leukemia stem cell regulation and resistance$403,983
R01 · FY2024 · CA · contact PI
Leukemia stem cell regulation and resistance$416,737
R01 · FY2023 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$345,634
R01 · FY2023 · CA · contact PI
Leukemia stem cell regulation and resistance$416,737
R01 · FY2022 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$345,634
R01 · FY2022 · CA · contact PI
Leukemia stem cell regulation and resistance$437,368
R01 · FY2021 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$352,688
R01 · FY2021 · CA · contact PI
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership$1,380,163
U54 · FY2020 · CA
Microenvironmental Regulation of Leukemia Stem Cells$352,688
R01 · FY2020 · CA · contact PI
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership$1,092,481
U54 · FY2019 · CA
Microenvironmental Regulation of Leukemia Stem Cells$352,688
R01 · FY2019 · CA · contact PI
Research Training Program in Basic and Translational Oncology$247,189
T32 · FY2018 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$305,025
R01 · FY2017 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$275,378
R01 · FY2017 · CA · contact PI
Research Training Program in Basic and Translational Oncology$219,856
T32 · FY2017 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$305,025
R01 · FY2016 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$275,378
R01 · FY2016 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$305,025
R01 · FY2015 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$275,378
R01 · FY2015 · CA · contact PI
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma$181,542
P50 · FY2015 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$338,142
R01 · FY2014 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$305,276
R01 · FY2014 · CA · contact PI
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma$159,847
P50 · FY2014 · CA · contact PI
Microenvironmental Regulation of Leukemia Stem Cells$348,600
R01 · FY2013 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$314,718
R01 · FY2013 · CA · contact PI
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma$223,042
P50 · FY2013 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$310,971
R01 · FY2012 · CA · contact PI
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma$190,267
P50 · FY2012 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$310,971
R01 · FY2011 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$320,589
R01 · FY2010 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$320,589
R01 · FY2009 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$304,444
R01 · FY2009 · CA · contact PI
CLINICAL TRIAL: A PHASE I DOSE ESCALATION STUDY OF LBH589 IN COMBINATION WITH IM$53,335
M01 · FY2009 · RR · contact PI
Regulation of Hematopoietic Stem Cell Self-renewal and Differentiation$41,500
R03 · FY2009 · HL · contact PI
ACQUISITION OF PERIPHERAL BLOOD STEM CELLS, PERIPHERAL BLOOD AND/OR BONE MARROW$6,957
M01 · FY2009 · RR · contact PI
Abnormalities in gene expression in therapy-related MDS$552,720
R01 · FY2008 · HL · contact PI
Human Hematopoietic Cell Transformation by BCR/ABL$360,546
R01 · FY2008 · HL · contact PI
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma$335,563
P50 · FY2008 · CA · contact PI
Resistance of CML Stem Cells to Imatinib (Gleevec)$321,555
R01 · FY2008 · CA · contact PI
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA (CML)$4,806
M01 · FY2008 · RR · contact PI
MECHANISMS OF RESPONSE AND RESISTANCE TO STI571 IN CML$3,605
M01 · FY2008 · RR · contact PI
ACQUISITION OF PERIPHERAL BLOOD STEM CELLS, PERIPHERAL BLOOD AND/OR BONE MARROW$1,201
M01 · FY2008 · RR · contact PI
Abnormalities in gene expression in therapy-related MDS$563,931
R01 · FY2007 · HL · contact PI
Human Hematopoietic Cell Transformation by BCR/ABL$360,546
R01 · FY2007 · HL · contact PI
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma$324,440
P50 · FY2007 · CA · contact PI
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA (CML)$6,783
M01 · FY2007 · RR · contact PI
MECHANISMS OF RESPONSE AND RESISTANCE TO STI571 IN CML$1,785
M01 · FY2007 · RR · contact PI
Abnormalities in gene expression in therapy-related MDS$580,700
R01 · FY2006 · HL · contact PI
Human Hematopoietic Cell Transformation by BCR/ABL$371,315
R01 · FY2006 · HL · contact PI
Resistance of CML stem cells to STI571 (Gleevec)$298,965
R01 · FY2006 · CA · contact PI
Transplant for Lymphoma:Therapy-Related Leukemia$176,108
P50 · FY2006 · CA · contact PI
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA (CML)$2,178
M01 · FY2006 · RR · contact PI
Abnormalities in gene expression in therapy-related MDS$611,852
R01 · FY2005 · HL
Human Hematopoietic Cell Transformation by BCR/ABL$380,250
R01 · FY2005 · HL
Resistance of CML stem cells to STI571 (Gleevec)$306,160
R01 · FY2005 · CA
Transplant for Lymphoma:Therapy-Related Leukemia$170,978
P50 · FY2005 · CA
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA (CML)$2,067
M01 · FY2005 · RR
Resistance of CML stem cells to STI571 (Gleevec)$306,160
R01 · FY2004 · CA
Transplant for Lymphoma:Therapy-Related Leukemia$165,999
P50 · FY2004 · CA
Autologous Transplantation for Patients with CML$18,187
M01 · FY2004 · RR
Mechanisms of Response and Resistance to STI571 in CML$8,559
M01 · FY2004 · RR
Restoration of Integrin Function in Chronic Myelogic Leukemia (CML)$3,209
M01 · FY2004 · RR
Resistance of CML stem cells to STI571 (Gleevec)$307,495
R01 · FY2003 · CA
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA BY INTERFERON$0
M01 · FY2002 · RR
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA BY INTERFERON$155,764
M01 · FY2001 · RR
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA BY INTERFERON$0
M01 · FY2001 · RR
RESTORATION OF INTEGRIN FUNCTION IN CML BY INTERFERON$103,600
R29 · FY2000 · CA
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA BY INTERFERON$35,553
M01 · FY2000 · RR
RESTORATION OF INTEGRIN FUNCTION IN CHRONIC MYELOGIC LEUKEMIA BY INTERFERON$0
M01 · FY2000 · RR